Odds of major postoperative cardiovascular morbidity reduced with increased time from COVID-19 diagnosis to surgery<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 14, 2022 (HealthDay News) — The odds of experiencing major postoperative cardiovascular morbidity are reduced with increased time from COVID-19 diagnosis to surgery, according to a study published online Dec. 14 in JAMA Network Open<\/em>.<\/p>\n John M. Bryant, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined the association between time to surgery after COVID-19 diagnosis and the risk for a composite of major postoperative cardiovascular morbidity events (deep vein thrombosis, pulmonary embolism, cerebrovascular accident, myocardial injury, acute kidney injury, and death) within 30 days after surgery in a single-center study. Data were included for 3,997 adults with a previous diagnosis of COVID-19 who underwent surgery from Jan. 1, 2020, to Dec. 6, 2021.<\/p>\n The researchers found that there was a median of 98 days from COVID-19 diagnosis to surgery. Overall, 12.1 percent of patients had a major postoperative adverse cardiovascular event. The rate of the composite outcome decreased in association with increased time from COVID-19 diagnosis to surgery (adjusted odds ratio, 0.99 per 10 days; 95 percent confidence interval, 0.98 to 1.00; P = 0.006). For the 1,552 patients who had received at least one dose of COVID-19 vaccine, this trend persisted (adjusted odds ratio, 0.98 per 10 days; 95 percent confidence interval, 0.97 to 1.00; P = 0.04).<\/p>\n “Understanding the potential benefits associated with delaying surgery provides a key step in clinicians’ ability to optimize surgical timing for the increasing population of patients who have been infected with COVID-19,” the authors write.<\/p>\n Two authors disclosed financial ties to the pharmaceutical industry.<\/p>\n